Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL760382 | 0.84 | EGFR (0.65) | EGFRKDM4EALDH1A1GLAGAA | |
| Quinoline SCHEMBL3706558 | 0.82 | ALDH1A1 (0.52) | EGFRKDM4AKDM4BKDM5CKDM4C | |
| Acridine SCHEMBL3851263 | 0.80 | ALDH1A1 (0.47) | EGFRKDM4EALDH1A1GLAGAA | |
| Purine SCHEMBL2120547 | 0.80 | KDM4A (0.38) | EGFRKDM4AKDM4BKDM5CKDM4C | |
| Purine SCHEMBL3157 | 0.80 | — | — | |
| Purine SCHEMBL29456595 | 0.80 | — | — | |
| Purine SCHEMBL6421376 | 0.80 | KDM4A (0.38) | EGFRKDM4AKDM4BKDM5CKDM4C | |
| Purine SCHEMBL1415387 | 0.79 | KDM4A (0.37) | EGFRKDM4AKDM4BKDM5CKDM4C | |
| Purine SCHEMBL7728593 | 0.79 | KDM4A (0.37) | EGFRKDM4AKDM4BKDM5CKDM4C | |
| Purine SCHEMBL625350 | 0.79 | KDM4A (0.37) | EGFRKDM4AKDM4BKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| US-9493467-B2 | PI3 kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2015752-B1 | P13 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-25 | — | — | US | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2004654-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2557080-A1 | Method for identifying pI3-kinase antagonists | The Regents of The University of California (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2551270-A2 | PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | The Regents of The University of California (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20060252926-A1 | Process for the preparation of pregnanes | SICOR, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1474435-B1 | PROCESS FOR THE PREPARATION OF 6-ALPHA FLUORINATED PREGNANES | SICOR INC (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1474435-A1 | PROCESS FOR THE PREPARATION OF PREGNANES | Sicor Inc. (US) | 2004-11-10 | — | — | EP | disclosed |
| US-6784295-B2 | CARRIED OUT IN THE PRESENCE OF AN INORGANIC BASE OR ORGANIC NITROGEN BASE AND A PALLADIUM COMPLEX CATALYST CONTAINING SECONDARY MONOPHOSPHINES WITH ALIPHATIC, BRANCHED OR CYCLIC SUBSTITUENTS AS LIGANDS | SOLVIAS AG (CH) | 2004-08-31 | — | — | US | disclosed |
| WO-2004052911-A1 | PROCESS FOR THE PREPARATION OF PREGNANES | SICOR INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | INDOLESE ADRIANO (CH) | 2003-09-25 | — | — | US | disclosed |
| EP-1132361-B1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6548684-B2 | Using monophosphine palladium complex catalyst | SOLVIAS AG (SE) | 2003-04-15 | — | — | US | disclosed |
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2001-11-01 | — | — | US | disclosed |
| EP-1132361-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | Solvias AG (CH) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | EGFR 2849/4885KDM4A 1197/4885KDM4B 964/4885 |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | EGFR 2849/4885KDM4A 1197/4885KDM4B 964/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | EGFR 359/4885KDM4A 3279/4885KDM4B 3523/4885 |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | AKT3, PRKD3, CDK13 | EGFR 1210/4885KDM4A 3599/4885KDM4B 4005/4885 |
| US-20060252926-A1 | Process for the preparation of pregnanes | CYP17A1, CYP21A2, NR5A1 | EGFR 2894/4885KDM4A 4660/4885KDM4B 4621/4885 |
| US-20110301144-A1 | Kinase Antagonists | MTOR, RPS6KA3, AKT3 | EGFR 359/4885KDM4A 3279/4885KDM4B 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.